Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. OTC Markets
  5. Synaptogenix, Inc.
  6. Summary
    SNPX   US87167T1025

SYNAPTOGENIX, INC.

(SNPX)
  Report
 SummaryQuotesChartsNewsCompanyFinancials 
Quotes 5-day view   Delayed Quote. Delayed Otc Markets
05/03/2021 05/04/2021 05/05/2021 05/06/2021 05/07/2021 Date
2.16(c) 2.06(c) 2.27(c) 2.0299(c) 2(c) Last
44 663 22 239 3 921 52 482 17 092 Volume
-9.62% -4.63% +10.19% -10.58% -1.47% Change
More quotes
Financials (USD)
Sales 2019 - - -
Net income 2019 -15,1 M - -
Net cash position 2019 17,4 M - -
P/E ratio 2019 -
Yield 2019 -
Sales 2020 - - -
Net income 2020 -12,7 M - -
Net cash position 2020 5,80 M - -
P/E ratio 2020 -0,50x
Yield 2020 -
Capitalization 28,1 M 28,1 M -
EV / Sales 2019 -
EV / Sales 2020 -
Nbr of Employees 4
Free-Float -
More Financials
All news about SYNAPTOGENIX, INC.
04/30SYNAPTOGENIX, INC.  : Financial Statements and Exhibits (form 8-K)
AQ
04/26SYNAPTOGENIX  : to Present at Sachs 4th Annual Neuroscience Innovation Forum
PR
04/08SYNAPTOGENIX, INC.  : Change in Directors or Principal Officers, Submission of M..
AQ
04/01SYNAPTOGENIX  : Announces Phase 2b Bryostatin-1 Clinical Trial Update
PR
03/30SYNAPTOGE  : SYNAPTOGENIX, INC. Management's Discussion and Analysis of Financia..
AQ
02/17SYNAPTOGENIX, INC.  : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
02/12SYNAPTOGENIX  : to Participate in the Winter Wonderland - Best Ideas from the Bu..
PR
02/04SYNAPTOGENIX  : Synthetic Bryostatin Available to Expand Neurodegenerative Indic..
PR
01/22SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Unregistered S..
AQ
01/19SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Material Modif..
AQ
2020SYNAPTOGENIX  : Management's Discussion and Analysis of Financial Condition and ..
AQ
2020SYNAPTOGENIX, INC.  : Regulation FD Disclosure, Financial Statements and Exhibit..
AQ
2020SYNAPTOGE  : Synaptogenix Schedules Business Update Conference Call
PR
2020SYNAPTOGENIX, INC.  : Entry into a Material Definitive Agreement, Material Modif..
AQ
More news
News in other languages on SYNAPTOGENIX, INC.

- No features available -

More news
Chart SYNAPTOGENIX, INC.
Duration : Period :
Synaptogenix, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Managers and Directors
NameTitle
Alan J. Tuchman Chief Executive Officer & Director
Daniel L. Alkon President, Director & Chief Science Officer
Robert Weinstein Chief Financial Officer, Secretary & Treasurer
Joshua Nathaniel Silverman Chairman
William S. Singer Vice Chairman